Vitiligo Signature-Based Drug Screening Identifies Fulvestrant as a Novel Immunotherapy Combination Strategy.

ABSTRACT: Immunotherapy has revolutionized cancer treatment; however, only 10-30% of patients experience durable survival benefits, while most malignancies remain resistant. In melanoma, vitiligo-like depigmentation is a frequent and generally mild immune-related adverse event, whose presence correlates positively with enhanced antitumor immune responses and prolonged patient survival. By performing comparative analyses between vitiligo and melanoma, we established a biomarker panel-designated the vitiligo signature (VGS)-that differentiates "cold" from "hot" tumors with high accuracy. Leveraging a deep learning-based efficacy prediction system (DLEPS), we identified and validated Fulvestrant as a candidate capable of enhancing anti-programmed cell death ligand 1 (PD L1) therapy in preclinical model

SUBMITTER: Zhu J 

PROVIDER: S-EPMC12667482 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature